Cargando…
Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes—specifically psychosis, agitation, or a combination. A c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847435/ https://www.ncbi.nlm.nih.gov/pubmed/32415541 http://dx.doi.org/10.1007/s10654-020-00643-2 |
_version_ | 1783644932270981120 |
---|---|
author | Mueller, Christoph John, Christeena Perera, Gayan Aarsland, Dag Ballard, Clive Stewart, Robert |
author_facet | Mueller, Christoph John, Christeena Perera, Gayan Aarsland, Dag Ballard, Clive Stewart, Robert |
author_sort | Mueller, Christoph |
collection | PubMed |
description | Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes—specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia diagnosis were determined according to the Health of the Nation Outcome Scales’ mental and behavioural problem scores and the sample was divided into four groups: ‘agitation and psychosis’, ‘agitation, but no psychosis’, ‘psychosis, but no agitation’, and ‘neither psychosis nor agitation’. Antipsychotic prescription in a one-year window around first dementia diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, functioning, as well as physical and mental health. Only in the group ‘psychosis, but no agitation’ (n = 579), 30% of whom were prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09–4.25). An increased antipsychotic-related all-cause (adjusted HR 1.14; 95% CI 1.04–1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01–1.63) was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting with psychosis without agitation, indicating the need for novel interventions for this group. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10654-020-00643-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7847435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-78474352021-02-08 Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes Mueller, Christoph John, Christeena Perera, Gayan Aarsland, Dag Ballard, Clive Stewart, Robert Eur J Epidemiol Psychiatric Epidemiology Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes—specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia diagnosis were determined according to the Health of the Nation Outcome Scales’ mental and behavioural problem scores and the sample was divided into four groups: ‘agitation and psychosis’, ‘agitation, but no psychosis’, ‘psychosis, but no agitation’, and ‘neither psychosis nor agitation’. Antipsychotic prescription in a one-year window around first dementia diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, functioning, as well as physical and mental health. Only in the group ‘psychosis, but no agitation’ (n = 579), 30% of whom were prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09–4.25). An increased antipsychotic-related all-cause (adjusted HR 1.14; 95% CI 1.04–1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01–1.63) was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting with psychosis without agitation, indicating the need for novel interventions for this group. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10654-020-00643-2) contains supplementary material, which is available to authorized users. Springer Netherlands 2020-05-15 2021 /pmc/articles/PMC7847435/ /pubmed/32415541 http://dx.doi.org/10.1007/s10654-020-00643-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Psychiatric Epidemiology Mueller, Christoph John, Christeena Perera, Gayan Aarsland, Dag Ballard, Clive Stewart, Robert Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes |
title | Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes |
title_full | Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes |
title_fullStr | Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes |
title_full_unstemmed | Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes |
title_short | Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes |
title_sort | antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes |
topic | Psychiatric Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847435/ https://www.ncbi.nlm.nih.gov/pubmed/32415541 http://dx.doi.org/10.1007/s10654-020-00643-2 |
work_keys_str_mv | AT muellerchristoph antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes AT johnchristeena antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes AT pereragayan antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes AT aarslanddag antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes AT ballardclive antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes AT stewartrobert antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes |